clinical trial · NCT03536884
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
UCB Biopharma SRL·phase3·completed·n = 743
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisBimekizumabSecukinumabPlacebo
brief summary
This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).
started
Jun 13, 2018
primary completion
Sep 12, 2019
completion
Aug 9, 2023
last updated
Apr 15, 2026
detailed description
The study consists of a 48-week double-blind Treatment Period, an optional 96-week open-label extension (OLE) Period and an optional 48-week OLE2 Period for eligible subjects in the USA and Canada.
official title
A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol